Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis

PURPOSE: Observations studies have shown that prior use of statins is associated with a reduced risk of adverse clinical outcomes in patients with COVID-19. However, the available data are limited, inconsistent and conflicting. Besides, no randomised controlled trial exists in this regard. Hence, th...

Full description

Bibliographic Details
Main Authors: Banerjee, M. (Author), Bhattacharjee, S. (Author), Pal, R. (Author), Yadav, U. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Online Access:View Fulltext in Publisher
LEADER 02486nam a2200193Ia 4500
001 10.1136-postgradmedj-2020-139172
008 220510s2022 CNT 000 0 und d
020 |a 14690756 (ISSN) 
245 1 0 |a Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis 
260 0 |b NLM (Medline)  |c 2022 
856 |z View Fulltext in Publisher  |u https://doi.org/10.1136/postgradmedj-2020-139172 
520 3 |a PURPOSE: Observations studies have shown that prior use of statins is associated with a reduced risk of adverse clinical outcomes in patients with COVID-19. However, the available data are limited, inconsistent and conflicting. Besides, no randomised controlled trial exists in this regard. Hence, the present meta-analysis was conducted to provide an updated summary and collate the effect of statin use on clinical outcomes in COVID-19 using unadjusted and adjusted risk estimates. METHODS: PubMed, Scopus and Web of Science databases were systematically searched using appropriate keywords till December 18 2020, to identify observational studies reporting clinical outcomes in COVID-19 patients using statins versus those not using statins. Prior and in-hospital use of statins were considered. Study quality was assessed using the Newcastle-Ottawa Scale. Unadjusted and adjusted pooled odds ratio (OR) with 95% CIs were calculated. RESULTS: We included 14 observational studies pooling data retrieved from 19 988 patients with COVID-19. All the studies were of high/moderate quality. Pooled analysis of unadjusted data showed that statin use was not associated with improved clinical outcomes (OR 1.02; 95% CI 0.69 to 1.50, p=0.94, I2=94%, random-effects model). However, on pooling adjusted risk estimates, the use of statin was found to significantly reduce the risk of adverse outcomes (OR 0.51; 95% CI 0.41 to 0.63, p<0.0005, I2=0%, fixed-effects model). CONCLUSIONS: Statin use is associated with improved clinical outcomes in patients with COVID-19. Individuals with multiple comorbidities on statin therapy should be encouraged to continue the drug amid the ongoing pandemic. © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. 
650 0 4 |a infectious diseases 
650 0 4 |a lipid disorders 
700 1 |a Banerjee, M.  |e author 
700 1 |a Bhattacharjee, S.  |e author 
700 1 |a Pal, R.  |e author 
700 1 |a Yadav, U.  |e author 
773 |t Postgraduate medical journal